PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
// Phaik Ju Teoh 1, 4 , Chonglei Bi 1 , Chirackal Sintosebastian 2 , Liang Seah Tay 3 , Rafael Fonseca 2 , Wee Joo Chng 1, 2, 4 1 Cancer Science Institute Singapore, National University of Singapore, Singapore 2 Department of Hematology-Oncology, Mayo Clinic, Scottsdale, Arizona, USA 3 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 4 Department of Haematology-Oncology, National University Cancer Institute, Singapore Correspondence to: Wee Joo Chng, email: csicwj@nus.edu.sg Keywords: multiple myeloma, PRIMA-1, ER stress, p73, bortezomib Received: May 05, 2016 Accepted: July 28, 2016 Published: August 12, 2016 ABSTRACT Despite therapeutic advancement, multiple myeloma (MM) remains incurable with drug resistance being one of the main challenges in the clinic. Myeloma cells possess high protein secretory load, leading to increased intracellular endoplasmic reticulum (ER) stress. Hence, they are vulnerable to further perturbation to its protein homeostasis. In studying the therapeutic mechanism of PRIMA-1 (mutant-p53-reactivating-agent), we uncovered its novel p53-independent-mechanism that can be exploited for myeloma. Despite its inability in restoring the wild type-p53 protein conformation and transcriptional function in the mutant-p53-human-myeloma-cells, PRIMA-1 was efficacious against myeloma cells with differential p53 genotypes. Strikingly, cells without p53 expression demonstrated highest drug sensitivity. Genome-wide gene-expression analysis revealed the involvement of ER stress/UPR-pathway in inducing PRIMA-1-toxicity. UPR markers, HSP70, CHOP and GADD34, were significantly up-regulated, concomitantly with the induction of apoptosis. Furthermore, there was a global attenuation of protein synthesis, correlated with phospho-eIF2a up-regulation. Mechanistically, we identified that PRIMA-1 could cause the demethylation of TP73 , through DNMT1 depletion, to subsequently enhance UPR. Of clinical significance, we observed that PRIMA-1 had additive therapeutic effects with another UPR-inducing-agent, bortezomib. Importantly, it can partially re-sensitize bortezomib-resistant cells to bortezomib. Given that MM is already stressed at the baseline in the ER, our results implicated that PRIMA-1 is a potential therapeutic option in MM by targeting its Achilles heel.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 2×
“PRIMA-1 (p53 reactivation and induction of massive apoptosis) is a small molecular drug that was functionally discovered to reactivate mutant p53 by restoring its WT (wild type) protein conformation, transcriptional activity and its ultimate tumour suppressive properties [9, 10].”
BackgroundPRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Mimura, N., Fulciniti, M., Gorgun, G., Tai, Y.-T., Cirstea, D., Santo, L., Hu, Y., Fabre, C., Minami, J., Ohguchi, H., et al. (2012) · Blood · doi:10.1182/blood-2011-07-366633 · Cited by 432 · cited 1×
“XBP1 splicing is the hallmark for IRE1 activation and has been reported to be an early event in UPR [24].”
BackgroundLehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 5×
“Of paramount importance, the first-in-human study with PRIMA-1Met has reported 60mg/kg as the maximum tolerated dose, which corresponds to a maximum plasma concentration of about 300uM [15].”
BackgroundInfluentialPRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252 · cited 1×
“Although PRIMA-1 has been reported to synergize with various cytotoxic drugs such as dexamethasone, doxorubicin and cisplatin [14, 16, 48], to the best of our knowledge, our study is the first to report the novel efficacy of PRIMA-1-bortezomib combination.”
BackgroundMeasuring Protein Synthesis With SUnSET: A Valid Alternative to Traditional Techniques?
Goodman, C. A., & Hornberger, T. A. (2013) · Exercise and Sport Sciences Reviews · doi:10.1097/jes.0b013e3182798a95 · Cited by 233
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183 · cited 1×
“Supporting this theory, the ability of PRIMA-1/MQ binding to other proteins (TrxR1 and glutathione) has been reported previously [42, 43].”
BackgroundPeng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.417 · Cited by 170
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
Tessoulin, B., Descamps, G., Moreau, P., Maïga, S., Lodé, L., Godon, C., Marionneau-Lambot, S., Oullier, T., Le Gouill, S., Amiot, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548800 · Cited by 166
Pharmacological reactivation of p53 as a strategy to treat cancer
Zawacka‐Pankau, J., & Selivanova, G. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12336 · Cited by 82
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Mutant p53 as a target for cancer treatment
Duffy, M. J., Synnott, N. C., & Crown, J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.023 · Cited by 364
Perdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M. (2017) · Cancers · doi:10.3390/cancers9120172 · Cited by 126
“The importance of UPR in PRIMA-1 anti-tumor impacts has been highlighted by Teoh et al. (2016)[54], knocking-down CHOP, a specific factor mediating the ER stress-induced apoptosis, that led to a significant cytotoxicity decrease in p53-null cells.”
BackgroundInfluentialSLC7A11 Is a Superior Determinant of APR-246 (Eprenetapopt) Response than TP53 Mutation Status
Fujihara, K. M., Corrales Benitez, M., Cabalag, C. S., Zhang, B. Z., Ko, H. S., Liu, D. S., Simpson, K. J., Haupt, Y., Lipton, L., Haupt, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0067 · Cited by 48
Metadata
- Authors
- Teoh, P. J., Bi, C., Sintosebastian, C., Tay, L. S., Fonseca, R., & Chng, W. J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-08-12
- Volume
- 7
- Issue
- 38
- Pages
- 61806-61819
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2514741988
- Cited by
- 28
- References
- 10
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.